Latest News for: phase i trial

Edit

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating

Hastings Tribune 15 Jul 2026
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone ... .
Edit

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low ...

Nasdaq Globe Newswire 14 Jul 2026
... trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
Edit

ORIC� Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination ...

Nasdaq Globe Newswire 14 Jul 2026
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone ... .
Edit

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

PR Newswire 14 Jul 2026
Our medicinal chemistry team advanced those hits into BGE-102, an oral, brain-penetrant molecule that engages a novel NLRP3 binding site and that produced profound hsCRP reductions in our Phase 1 trial.
Edit

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

Nasdaq Globe Newswire 13 Jul 2026
... clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate.
Edit

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial (Zelluna ASA)

Public Technologies 13 Jul 2026
* First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The ... given the first dose in ZIMA-101, the Company's first-in-human Phase 1 clinical ... very innovative first-in-human early-phase trial, which will inform the next.
Edit

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease (Form 8-K) (Annovis Bio Inc)

Public Technologies 10 Jul 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease. Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections.
Edit

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

The Milton Standard Journal 09 Jul 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Jul 9, 2026-- ....
Edit

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (Form 8-K) (Ionis Pharmaceuticals Inc)

Public Technologies 09 Jul 2026
) Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy ... IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 ...
Edit

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (Ionis Pharmaceuticals Inc)

Public Technologies 09 Jul 2026
CARDIO-TTRansform is a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of eplontersen in adults with wild-type or hereditary ATTR-CM who are receiving available standard of care therapy.
Edit

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis (Form 6-K) (Chemomab Therapeutics Ltd)

Public Technologies 08 Jul 2026
Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis ... precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher's AI Network ... a Phase 2 trial.
Edit

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis (Chemomab Therapeutics Ltd)

Public Technologies 08 Jul 2026
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis ... A topline readout of the RA Phase 2 trial results is expected in H1 2028.
Edit

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Caledonian Record 07 Jul 2026
LONDON & NEW YORK--(BUSINESS WIRE)--Jul 7, 2026-- ....
Edit

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Nasdaq Globe Newswire 07 Jul 2026
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections ... .
Edit

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity ...

Nasdaq Globe Newswire 07 Jul 2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD ... .

Article Search

tools
×
×
×
×